Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00214110 · ClinicalTrials.gov registry record · Phase 2
Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00214110 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 100 participants.
The verdict
NCT00214110, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This is a single-center, phase 2 randomized clinical trial of tamoxifen on mean percent predicted isometric muscle strength in patients with amyotrophic lateral sclerosis (ALS). The purpose is to determine whether the triphenylethylenetamoxifen, used as adjuvant therapy in the treatment of breast cancer, can delay the loss of isometric muscle strength in ALS patients.
Interventions
- DRUG Tamoxifen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2001-01 |
| Est. Completion | 2005-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00214110
The ClinicalTrials.gov registry entry for NCT00214110 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tamoxifen is the first listed.
NCT00214110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00214110 about?
NCT00214110 is a clinical study titled "Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]". This is a single-center, phase 2 randomized clinical trial of tamoxifen on mean percent predicted isometric muscle strength in patients with amyotrophic lateral sclerosis (ALS). The purpose is to determine whether the triphenylethylenetamoxifen, used as adjuvant therapy in the treatment of breast ca...
What is the current status of trial NCT00214110?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2001-01. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00214110?
The interventions under investigation include: Tamoxifen (DRUG).
Who is sponsoring clinical trial NCT00214110?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.